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Abstract
Background: Risk of pneumocystosis after discontinuation of primary or secondary prophylaxis among HIV-infected 
patients before CD4 counts increase to ^200 cells/μL (early discontinuation) after receiving highly active antiretroviral 
therapy (HAART) is rarely investigated.
Methods: Medical records of 660 HIV-infected patients with baseline CD4 counts <200 cells/μL who sought HIV care 
and received HAART at a university hospital in Taiwan between 1 April, 1997 and 30 September, 2007 were reviewed to 
assess the incidence rate of pneumocystosis after discontinuation of prophylaxis for pneumocystosis.
Results: The incidence rate of pneumocystosis after HAART was 2.81 per 100 person-years among 521 patients who 
did not initiate prophylaxis or had early discontinuation of prophylaxis, which was significantly higher than the 
incidence rate of 0.45 per 100 person-years among 139 patients who continued prophylaxis until CD4 counts 
increased to ^200 cells/μL (adjusted risk ratio, 5.32; 95% confidence interval, 1.18, 23.94). Among the 215 patients who 
had early discontinuation of prophylaxis after achievement of undetectable plasma HIV RNA load, the incidence rate of 
pneumocystosis was reduced to 0.31 per 100 person-years, which was similar to that of the patients who continued 
prophylaxis until CD4 counts increased to ^200 cells/μL (adjusted risk ratio, 0.63; 95% confidence interval, 0.03, 14.89).
Conclusions: Compared with the risk of pneumocystosis among patients who continued prophylaxis until CD4 counts 
increased to ^200 cells/μL after HAART, the risk was significantly higher among patients who discontinued prophylaxis 
when CD4 counts remained <200 cells/μL, while the risk could be reduced among patients who achieved 
undetectable plasma HIV RNA load after HAART.
Background
With the widespread use of highly active antiretroviral
therapy (HAART) after 1996, HIV-related mortality and
the risks of several major opportunistic infections, such
as Pneumocystis jirovecii pneumonia (formerly P. carinii
pneumonia), disseminated Mycobacterium avium com-
plex infection, and cytomegalovirus diseases, have signif-
icantly declined in patients receiving HAART [1-3]. For
example, an incidence rate of 20 cases of pneumocystosis
per 100 person-months was reported in the pre-HAART
era [4], which decreased to 1.2 cases per 100 person-years
(100 PY) of follow-up in the era of antimicrobial prophy-
laxis for pneumocystosis and HAART [5]. In the HAART
era, the majority of cases of pneumocystosis occur in
patients who are unaware of their HIV infection or have
delay in seeking HIV care, or in those with advanced
immunosuppression (CD4+ count < 100 cells/μL) who
have limited access to HAART and related HIV care [6,7].
In the guidelines recommended by the National Insti-
tutes of Health, the Centers for Disease Control and Pre-
vention, and the HIV Medicine Association of the
Infectious Diseases Society of America [8], HIV-infected
patients should receive trimethoprim-sulfamethoxazole
(TMP-SMX) as primary prophylaxis for pneumocystosis
if they have CD4 counts of <200 cells/μL. Primary pro-
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phylaxis for pneumocystosis can be discontinued in HIV-
infected patients who respond favorably to HAART with
an increase in CD4 counts to >200 cells/μL for >3
months. For those who develop pneumocystosis, second-
ary prophylaxis can be discontinued when their CD4
counts increase from < 200 cells/μL to ^200 cells/μL for
more than 3 months as a result of HAART. Several obser-
vational studies and clinical trials have shown that the
risk of pneumocystosis is low when primary or secondary
prophylaxis is discontinued after CD4 count increases to
^200 cells/μL. In a meta-analysis of 14 published studies,
the incidence rate of pneumocystosis was estimated 0.24
per 100 PY and 0.20 per 100 PY in patients who discon-
tinued primary and secondary prophylaxis, respectively,
after CD4 counts increased to ^200 cells/μL [9].
Prophylaxis or treatment with TMP-SMX is not with-
out problem, however. Skin rashes and fever are the most
common adverse effects of TMP-SMX in HIV-infected
patients in addition to neutropenia, gastrointestinal intol-
erance or Stevens-Johnson syndrome [10]. Due to
adverse effects of TMP-SMX and limited availability of
the alternative agents for prophylaxis, such as
pyrimethamine, dapsone, atovaquone, and pentamidine,
a certain proportion of the patients that are in need of
primary or secondary prophylaxis according to the guide-
lines may have to discontinue prophylaxis before their
CD4 counts increase to ^200 cells/μL. However, studies
to assess the safety of early discontinuation of prophylaxis
for pneumocystosis before the CD4 counts increase to
^200 cells/μL have not been performed until recently
when D'Egidio and colleagues followed 19 HIV-infected
patients with sustained HIV RNA levels < 50 copies/ml
and a median of CD4 count of 120 cells/μL who discon-
tinued secondary prophylaxis without relapse after an
observation duration of 13.7 months [11]. Though lim-
ited by a small sample size and a short observation dura-
tion, this study suggests that discontinuation of
prophylaxis for pneumocystosis may be safe in selected
patients who continue to receive HAART despite of low
CD4 counts.
In this study, we aimed to assess the risk of pneumocys-
tosis among HIV-infected patients with baseline CD4
counts of <200 cells/μL who discontinued primary or sec-
ondary prophylaxis before their CD4 counts increased to
^200 cells/μL after receipt of HAART.
Methods
Study population
Between 1 April, 1997 and 30 September, 2007, consecu-
tive HIV-infected patients who sought HIV care at the
National Taiwan University Hospital were enrolled in an
observational study to assess the impact of HAART on
the incidences of AIDS-defining opportunistic illnesses.
The study protocol has been described before [12,13]. In
brief, a standardized case record form was used to record
patient characteristics, baseline and sequential CD4
counts and plasma HIV RNA load (PVL), antimicrobial
prophylaxis or treatment, antiretroviral therapy, occur-
rence of AIDS-defining opportunistic illnesses at baseline
and during follow-up, pneumonia or other bacterial
infections, and parasitic infections.
To assess the impact of HAART on the incidence rate
of pneumocystosis, we identified patients who had base-
line CD4 counts of <200 cells/μL and had been followed
up for more than 3 months. Patients who were lost to fol-
low-up or died within 3 months of enrollment were
excluded (Figure 1).
Prophylaxis for pneumocystosis and HAART
In Taiwan, HIV-infected patients are provided free-of-
charge access to HIV care, including HAART that was
introduced on 1 April, 1997, at several designated hospi-
tals around Taiwan. HAART consists of two nucleoside
reverse-transcriptase inhibitors plus non-nucleoside
reverse-transcriptase inhibitors or protease inhibitors; or
triple nucleoside reverse-transcriptase inhibitors. TMP-
SMX (80/400 mg) has been the recommended treatment
and prophylaxis for pneumocystosis. For those patients
who are unable to tolerate TMP-SMX, prophylaxis or
treatment is replaced with clindamycin plus primaquine
[14]. Atovaquone, pyrimethamine and dapsone are not
available for pneumocystosis prophylaxis in Taiwan,
while pentamidine was available only before 1997. The
Figure 1 Study population of Pneumocystis jirovecii pneumonia 
after discontinuation of primary or secondary prophylaxis be-
tween April 1997 and December 2007.
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decision of discontinuation of prophylaxis or switch to
clindamycin plus primaquine for pneumocystosis in the
face of adverse effects of TMP-SMX has been made by
the treating physicians.
Follow-up and end points
After initiation of HAART, patients received follow-up at
an interval of 1 to 3 months. Each visit included a medical
history taking, a general physical examination, and labo-
ratory tests including complete blood counts with differ-
ential count and blood biochemistry. CD4 count and PVL
were determined before and 1 month after HAART and
every 3-4 months thereafter. A chest radiograph and
microbiological investigations were performed when
patients presented with respiratory symptoms or a his-
tory of prolonged fevers or wasting.
Pneumocystosis was confirmed when cytology or his-
topathology of respiratory specimens disclosed cysts or
trophozoites by special stains; pneumocystosis was con-
sidered presumptive if the patients presented with typical
symptoms (resting or exertional dyspnea, nonproductive
cough, hypoxemia, and elevated lactate dehydrogenase
levels), plus radiographic manifestations of interstitial
pneumonitis who responded to any of the standard rec-
ommended treatments for pneumocystosis.
Other than pneumocystosis, we also assessed the inci-
dence of bacterial infection and parasitic infection after
discontinuation of primary or secondary prophylaxis. A
diagnosis of bacterial infection was made on microscopy
and cultures of relevant clinical specimens and a compat-
ible clinical history that included an acute onset of symp-
toms, with a response to anti-bacterials that have no
known activity against pneumocystosis. Parasitic infec-
tions of interest were amebiasis, giardiasis, cryptosporidi-
osis, isoporiasis, cyclosporiasis, and toxoplasma
encephalitis. The study was approved by Research Ethics
Committee of the National Taiwan University Hospital
on 25 July, 2001 (reference number: 19011). The study
was conducted through periodic review of medical
records retrospectively and was waived for informed con-
sent.
Statistical analysis
The observation duration for occurrence of pneumocys-
tosis was estimated from the date of discontinuation of
primary or secondary prophylaxis to the date of diagnosis
of pneumocystosis, loss to follow-up at this hospital, or
death, or the end of the study on 31 December, 2007,
whichever occurred first. For patients who discontinued
primary or secondary prophylaxis before the CD4 counts
increased to 200 cells/μL (early discontinuation), the end
date of observation was the mid-point between the last
date when the patient's CD4 count was <200 cells/μL and
the first date when the patient's CD4 count increased to
^200 cells/μL.
All statistical analyses were performed using statistical
software programs (SAS version 8.1; SAS Institute Inc,
Cary, NC and STATA 10; College Station, Texas, USA).
Categorical variables were expressed as proportions and
compared using χ2 by Fisher exact test (2-tailed). The
incidence rate for each group was calculated as the num-
ber of cases of pneumocystosis, bacterial infection or par-
asitic infection per 100 PY of observation. Exact 95%
confidence intervals (95% CI) for incidence rates were
calculated on the basis of the Poisson distribution.
Results
Patient characteristics
Between April 1997 and September 2007, 660 patients
fulfilled the inclusion criteria (Figure 1): 165 patients with
baseline CD4 counts of <200 cells/μL did not receive pri-
mary prophylaxis for pneumocystosis; and 279 and 216
patients received primary and secondary prophylaxis,
respectively. Their demographic and clinical characteris-
tics at enrollment are shown in Table 1. Most patients
were men, and the risk factor of HIV transmission was
predominantly sexual contact.
Among the 279 patients who received primary prophy-
laxis for pneumocystosis, 211 (75.6%) had early discon-
tinuation of prophylaxis, and 68 (24.4%) continued
prophylaxis until CD4 increased to ^200 cells/μL (Table
1). Compared with the latter group of patients, the former
group of patients were older (mean age, 39 vs 35 years; P
= 0.03) and had a lower baseline CD4 count (median, 27
vs. 93 cells/μL; P < 0.001), while both groups of patients
had similar baseline PVL (median, 5.46 vs 5.60 log10 cop-
ies/ml; P = 0.13). Forty-seven (16.8%) patients were lost to
follow-up in this group.
Among the 216 patients who received secondary pro-
phylaxis, 145 (67.1%) had early discontinuation of pro-
phylaxis, and 71 (32.9%) continued prophylaxis until CD4
increased to ^200 cells/μL (Table 1). Compared with the
latter group of patients, the former group of patients were
older (mean, 38.6 vs. 35 years; P = 0.006), had a lower
baseline CD4 count (median, 17 vs. 40 cells/μL; P < 0.001)
and had a lower baseline PVL (median, 5.56 vs 5.72 log10
copies/ml;  P  = 0.04) (Table 1). Twenty-three (10.6%)
patients were lost to follow-up in this group.
Among the 165 patients who did not receive primary or
secondary prophylaxis, the median baseline CD4 count
was 134 cells/μL, and PVL was 5.14 log10 copies/ml (Table
1). Forty-four (26.6%) patients were lost to follow-up.
Duration of prophylaxis and latest CD4 counts after HAART
The median duration of primary prophylaxis for pneu-
mocystosis was significantly shorter for the 211 patients
who had early discontinuation of prophylaxis than for the
68 patients who continued prophylaxis until CD4 count
increased to ^200 cells/μL (2.0 vs. 5.3 months). AlthoughCheng et al. BMC Infectious Diseases 2010, 10:126
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Table 1: Characteristics of 495 patients who received prophylaxis and 165 patients who did not receive prophylaxis
Characteristics Primary prophylaxis Secondary prophylaxis No prophylaxis
CD4 <200/μL CD4 ^200/μL P value CD4 <200/μL CD4 ^200/μL P value
Patient number, n 211 68 145 71 165
Age at enrollment, mean (SD), y 39.0 (12.0) 35.0 (10.7) 0.03 38.6 (10.2) 35.0 (8.4) 0.006 37.0 (10.9)
Male sex, n (%) 195 (92.4) 66 (97.1) 0.26 134 (92.4) 68 (95.8) 0.56 152 (92.1)
Risk behaviors, no (%)
MSM 138 (65.4) 48 (70.6) 0.74 89 (61.4) 58 (81.7) 0.22 110 (66.7)
Heterosexual 68 (32.2) 17 (25.0) 0.47 50 (34.5) 10 (14.1) 0.02 41 (24.8)
Others 5 (2.4) 3 (4.4) 0.41 6 (4.1) 3 (4.2) 0.99 14 (8.5)
Nadir CD4 count, median (range), 
cells/μL
27 (1-182) 93 (67-194) <0.001 17 (0-165) 40 (1-174) <0.001 134 (4-199)
Baseline PVL, median (range), 
log10 copies/ml
5.46 (2.60-6.12) 5.60 (2.60-6.19) 0.13 5.56 (2.60-5.99) 5.72 (3.09-5.98) 0.04 5.14 (2.60-5.88)
Chemoprophylaxis, n (%)
Trimethoprim-
sulfamethoxazole
207 (98.1) 67 (98.5) 1 142 (97.9) 71 (100) 1 NA
Clindamycin/primaquine 2 (0.9) 2 (2.9) 0.26 29 (20.0) 15 (21.1) 0.86 NA
Macrolides 16 (9.0) 5 (7.4) 1 6 (4.1) 7 (9.9) 0.14 NA
Duration of prophylaxis, median 
(range), m
2.0 (0.2-66.2) 5.3 (0.25-47.8) 0.036 2.7 (0.1-62) 4.0 (0.34-57) 0.04
CD4 at discontinuation of 
prophylaxis
median (range), cells/ul 101 (2-199) 234 (207-642) <0.001 111 (5-197) 279 (201-880) <0.001
<100 cells/ul, n (%) 101 (47.9) 0 (0) 53 (36.6) 0 (0)
PVL at discontinuation of 
prophylaxis, median (range), 
log10 copies/ml
2.60 (2.60-5.88) 2.60 (2.60-5.15) 0.027 2.60 (2.60-5.88) 2.60 (2.60-5.51) 0.022 NA
PVL < 400 copies/ml, no (%) 130 (61.6) 55 (80.9) 0.24 85 (58.6) 53 (74.6) 0.31 NA
Latest CD4, median (range), cells/
ul
200 (2-214) 376 (0-952) 0.019 200 (2-215) 426 (2-1124) 0.005 200 (4-209)
<200 cells/ul, n (%) 78 (37.0) 15 (22) 0.11 41 (28.3) 10 (14.1) 0.09 49 (29.7)
Abbreviations: MSM. Men who have sex with men; NA, not applicable; PVL, plasma HIV RNA load
CD4 counts continued to increase with HAART (data not
shown), the median CD4 count of patients who had early
discontinuation of prophylaxis at the end of observation
was significantly lower than that of the patients who con-
tinued prophylaxis until CD4 increased to ^200 cells/μL
(200 vs. 376 cells/μL) (table 1).
The median duration of secondary prophylaxis for
pneumocystosis was significantly shorter for the 145
patients who had early discontinuation of prophylaxis
than for the 71 patients who continued prophylaxis until
CD4 increased to ^200 cells/μL (2.7 vs. 4.0 months). The
median CD4 count of the patients who had early discon-
tinuation of prophylaxis at the end of observation was
also lower than that of the patients who continued pro-
phylaxis until CD4 increased to ^200 cells/μL (200 vs. 426
cells/μL) (table 1).
Among the 165 patients who did not receive any pro-
phylaxis, their median CD4 count at the end of observa-
tion was 200 cells/μL (4-209) after follow-up for 7.6
months while they continued HAART.
Incidence of events during Follow-up
The crude incidence of adverse effects of primary pro-
phylaxis with TMP-SMX was estimated 23.3%, which
included skin rashes (13.3%), leucopenia (6.8%), gastroin-
testinal intolerance (2.9%), and Stevens-Johnson syn-
drome (0.4%). Among the 211 patients who had early
discontinuation of primary prophylaxis, 11 cases of pneu-
mocystosis were diagnosed after an observation duration
of 366 PY (incidence rate, 3.0 per 100 PY; 95% CI, 1.50 to
5.38). These 11 episodes of presumptive diagnosis of
pneumocystosis occurred in patients with a median CD4
count of 33 cells/μL (range, 8-138) after a median obser-Cheng et al. BMC Infectious Diseases 2010, 10:126
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vation of 13.7 months (range, 2.2-92.4) in the absence of
primary prophylaxis. Those episodes occurred in patients
with frequent losses to follow-up for more than 1 year (9
patients) or poor compliance with HAART (2). Among
the 68 patients who discontinued primary prophylaxis
after CD4 counts increased to ^200 cells/μL, 1 case of
pneumocystosis was diagnosed with an incidence rate of
0.43 per 100 PY (95% CI, 0.01 to 2.38). In the meantime,
53 episodes of bacterial infections were diagnosed in
patients who had early discontinuation of primary pro-
phylaxis, yielding an incidence rate of 14.48 per 100 PY
(95% CI, 10.85 to 18.94), while 13 episodes were diag-
nosed in the patients who discontinued primary prophy-
laxis after CD4 counts increased to ^200 cells/μL,
yielding an incidence rate of 5.56 per 100 PY (95% CI,
2.96 to 9.50) (P < 0.001). The types of bacterial infections
of the former group included skin and soft tissue infec-
tions (34 cases), community-acquired pneumonia (7),
urinary tract infection (5) and bacteremia due to methi-
cillin-resistant  Staphylococcus aureus, non-tuberculous
mycobacteria or non-typhoid Salmonella (7). Two epi-
sodes of parasitic infection (toxoplasmosis), with an inci-
dence rate of 0.54 per 100 PY (95% CI, 0.07 to 1.97),
occurred in the patients who had early discontinuation of
primary prophylaxis.
Forty-seven patients (21.8%) developed adverse effects
that prompted discontinuation of secondary prophylaxis;
those adverse effects included skin rashes (17.6%), gastro-
intestinal intolerance (2.3%) and leucopenia (1.9%).
Among the 145 patients who had early discontinuation of
secondary prophylaxis, 6 cases of pneumocystosis were
diagnosed with an incidence rate of 2.49 per 100 PY (95%
CI, 0.91 to 5.42) (Table 2). These 6 cases of presumptive
pneumocystosis occurred in patients with a median CD4
count of 4 cells/μL (range, 1-40) after a median observa-
tion of 22.8 months (range, 8.3-69.3) in the absence of
secondary prophylaxis. All of the episodes occurred in
patients who had poor compliance with HAART and
virologic failure. The incidence rate of pneumocystosis
was 0.48 per 100 PY (95% CI, 0.01 to 2.65) in the 71
patients who discontinued secondary prophylaxis after
CD4 counts increased to ^200 cells/μL. In total, 21 epi-
sodes of bacterial infections were diagnosed in patients
who had early discontinuation of secondary prophylaxis,
yielding an incidence rate of 8.71 per 100 PY (95% CI,
5.39 to 13.32); and 7 episodes were diagnosed in patients
who discontinued secondary prophylaxis after CD4
counts increased to ^200 cells/μL, yielding an incidence
rate of 3.33 per 100 PY (95% CI, 1.34 to 6.87). The types of
bacterial infections in the former group included skin and
soft tissue infections (13 cases), community-acquired
pneumonia (4), urinary tract infection (1) and bacteremia
due to S. aureus or non-typhoid Salmonella (3). Two epi-
sodes of parasitic infections (one amebiasis and one giar-
diasis), occurred in patients who had early
discontinuation of secondary prophylaxis, yielding an
incidence rate of 0.83 per 100 PY (95% CI, 0.10 to 3.00).
The incidence rate of pneumocystosis in 165 patients
with baseline CD4 counts of <200 cells/μL who did not
receive either primary or secondary prophylaxis for
pneumocystosis was 2.88 per 100 PY (95% CI, 0.59 to
8.43) (Table 2). Twenty-two episodes of bacterial infec-
tions (incidence rate, 21.16 per 100 PY [95% CI, 13.35 to
32.03]) and two episodes of parasitic infections (1 amebi-
asis and 1 toxoplasmosis) (incidence rate, 1.92 per 100 PY
[95% CI, 0.23 to 6.95]) were diagnosed. The types of bac-
terial infections included skin and soft tissue infections
(13 cases), community-acquired pneumonia (3), urinary
tract infection (2) and bacteremia due to Escherichia coli
or non-typhoid Salmonella (4).
When patients who did not initiate prophylaxis or had
early discontinuation of prophylaxis for pneumocystosis
were analyzed together, 20 cases of pneumocystosis
developed after a total observation duration of 711 PY,
with an incidence rate of 2.81 per 100 PY (95% CI, 1.72,
4.34). Among the 139 patients who continued primary or
secondary prophylaxis after CD4 counts increased to
^200 cells/μL after HAART, 2 cases of pneumocystosis
developed after a total observation duration of 444 PY,
with an incidence rate of 0.45 per 100 PY (95% CI, 0.05,
1.63). The risk of pneumocystosis was significantly higher
in the former group of patients than in the latter group,
with a risk ratio of 5.32 (95% CI, 1.18, 23.94; P = 0.03)
after adjustment for age, sex, risk for HIV transmission,
and baseline CD4 and PVL.
Among the 215 patients who achieved undetectable
PVL and had early discontinuation of primary of second-
ary prophylaxis for pneumocystosis, only one patient
developed pneumocystosis after a total observation dura-
tion of 323 PY (incidence rate, 0.31 per 100 PY [95% CI,
0.01, 1.71]). The adjusted risk ratio for pneumocystosis
was 0.63 (95% CI, 0.03, 14.89; P = 0.77) when the risk of
these patients compared to that of the patients who dis-
continued primary or secondary prophylaxis after CD4
counts increased to ^200 cells/μL.
Discussion
In this study, we have found that, compared with the
patients who continued primary or secondary prophy-
laxis for pneumocystosis until CD4 counts increased to
^200 cells/μL after HAART, patients who had early dis-
continuation of prophylaxis were at a significantly higher
risk for pneumocystosis, especially among those patients
who did not adhere to HAART. In the subgroup analysis,
the risk of pneumocystosis could be significantly reduced
if the patients who had early discontinuation of prophy-
laxis complied with HAART and achieved undetectable
PVL.Cheng et al. BMC Infectious Diseases 2010, 10:126
http://www.biomedcentral.com/1471-2334/10/126
Page 6 of 8
The incidence rate of pneumocystosis following dis-
continuation of primary and secondary prophylaxis
among HIV-infected patients when their CD4 counts
increased to ^200 cells/μL after receiving HAART in pub-
lished studies ranges from 0 to 2.27 cases per 100 PY of
follow-up, depending on the types of study design and
observation duration [3,11,15-25]. In our patients who
followed the guidelines for discontinuation of pneumo-
cystosis prophylaxis, the overall incidence was 0.45 per
100 PY (95% CI, 0.05, 1.63), which is within the range of
reported incidence rates of case series and cohort studies
(Table 3).
Discontinuation of prophylaxis before CD4 counts
increase to ^200 cells/μL after HAART has been per-
formed in some selected patients in published observa-
tional studies [11,15,17]. In one study, primary or
secondary prophylaxis was discontinued when CD4
count was <200 cells/μL in 98 patients who received
HAART without occurrence of pneumocystosis [15]. In a
recent study by D'Egidio et al. [11], no recurrence of
pneumocystosis was demonstrated in 19 patients who
had a median CD4 count of 120 cells/μL and achieved
sustained HIV viral suppression before prophylaxis for
pneumocystosis was discontinued during the mean fol-
low-up duration of 13.7 months. The observations of
increased overall risk for pneumocystosis in our patients
with early discontinuation of prophylaxis and reduced
risk for pneumocytosis in those patients who achieved
undetectable PVL suggest that decision of earlier discon-
tinuation of prophylaxis should only be cautiously made
in selected patients who have a favorable immunologic or
virologic response to HAART.
Earlier discontinuation of TMP-SMX or other alterna-
t i v e s  i n  t h e  p a t i e n t s  w i t h  i n c r e a s i n g  C D 4  c o u n t s  m a y
reduce pill burden, risk for adverse effects of TMP-SMX
that was noted in one fourth of our patients, and risk for
emergence of drug-resistant bacteria [26-28]. However,
the benefit should be balanced against the risk because
use of TMP-SMX is associated with decreased risk for
bacterial infections [29,30]. In our study, the incidence
rate of all-cause bacterial infection was estimated 8.71-
21.16 per 100 PY of follow-up after discontinuation of
prophylaxis for pneumocystosis, which appears to be
higher than those of previous studies, which ranged from
1.99 to 12.21 per 100 PY of follow-up [19-22].
Our findings that most of the cases of pneumocystosis
occurred in patients who did not have good adherence to
HAART and HIV care should alert clinicians and patients
with respect to the risk for pneumocystosis if decision of
early discontinuation of prophylaxis has to be made in the
face of adverse effects of antibacterial agents. For those
who have to discontinue primary or secondary prophy-
laxis due to intolerance or adverse effects, adherence to
HAART can not be overemphasized. Reinstitution of
prophylaxis should be considered once immunologic fail-
ure occurs after virologic failure to HAART due to poor
Table 2: Outcomes of patients who discontinued prophylaxis before and after cd4 count increase to ^200 cells/μl and 
patients who did not initiated prophylaxis for pneumocystosis
Outcome Primary prophylaxis Secondary prophylaxis No prophylaxis
CD4 <200/μL CD4 ^200/μL P value CD4 <200/μL CD4 ^200/μL P value
Patient number, n 211 68 145 71 165
New/recurrent episodes of PCP, n 11 1 6 1 3
Time from discontinuation of 
prophylaxis to PCP, median, M
13.7 (2.2-92.4) 74.5 22.8 (8.3-69.3) -20.7
CD4 count when new PCP 
developed, median, cells/μl
33 (8-138) 9 4 (1-40) -13 5 (0-87)
Total observation duration, PY 366 234 241 210 104
Incidence of new/recurrent PCP, 
per 100 PY (95% CI)
3.00 (1.26-4.76) 0.43 (0.01-
2.38)
0.03 2.49 (0.91-5.42) 0.48 (0.01-
2.65)
0.13 2.88 (0.59-8.43)
Episodes of bacterial infection, n 53 13 21 7 22
Incidence of bacterial infection, per 
100 PY (95% CI)
14.48 (10.85-
18.94)
5.56 (2.96-
9.50)
<0.001 8.71 (5.39-13.32) 3.33 (1.34-
6.87)
0.03 21.16 (13.35-
32.03)
Episodes of parasitic infection, n 2 0 2 0 2
Incidence of parasitic infection, per 
100 PY (95% CI)
0.54 (0.07-1.97) 0 0.83 (0.10-3.00) 0 1.92 (0.23-6.95)
Death, n (%) 23 (10.9) 4 (5.9) 0.35 8 (5.5) 1 (1.4) 0.28 22 (13.3)
Patients lost to follow-up, n (%) 40 (19.0) 7 (10.3) 0.19 16 (11.0) 8 (11.3) 1 44 (26.6)
Abbreviations: CI, confidence interval; PCP, Pneumocystis jirovecii pneumonia; PY, persons-yearsCheng et al. BMC Infectious Diseases 2010, 10:126
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compliance and emergence of HIV that is antiretroviral-
resistant.
There are several limitations of our study and interpre-
tation of our study should be cautious. First, this is not a
clinical trial to compare the risk for pneumocystosis
between patients who discontinue primary or secondary
prophylaxis when their CD4 counts remain < 200 cells/μL
and those who discontinue prophylaxis when their CD4
counts increase to ^200 cells/μL. Second, the decision of
discontinuation of prophylaxis was made by treating phy-
sicians based on individualized assessment, which may be
affected by uncontrolled factors. By medical record
review, we were not able to know the reasons why the
treating physicians discontinued prophylaxis earlier
before CD4 increased to the recommended cut-off value
by the guidelines. Third, the diagnosis of pneumocystosis
was based on clinical suspicion and an appropriate
response to any of the recommended standard treat-
ments and the absence of evidence of bacterial pneumo-
nia. All of our diagnoses were presumptive, not definitive.
Fourth, the results of this study of early discontinuation
of pneumocystosis prophylaxis may not be generalized to
the patients with virologic and immunological failure or
the patients with limited access to HAART and HIV care.
Last, the benefits of TMP-SMX in resource-limited set-
tings are multiple in addition to its low cost, and continu-
ation of TMP-SMX can protect patients from several
bacterial or parasitic infections [31-33]. In such settings,
benefits of continuation of TMP-SMX may still outweigh
the risks associated with earlier discontinuation of TMP-
SMX after programs of antiretroviral therapy is increas-
ingly implemented in these regions.
Conclusions
The overall risk of pneumocystosis in patients on
HAART was low in Taiwan. Patients who had early dis-
continuation of prophylaxis for pneumocystosis were
associated with a higher risk of pneumocystosis and bac-
terial infections than those who continued prophylaxis
until CD4 increased to ^200 cells/μL after HAART. The
risk of pneumocystosis was lower in those patients who
had early discontinuation of prophylaxis while achieving
complete virologic response to HAART.
List of abbreviations
95% CI: 95%confidence interval; HAART: highly active
antiretroviral therapy; HIV: human immunodeficiency
virus; PVL: plasma HIV RNA load; 100 PY: 100 person-
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